Pimavanserin is an antagonist/inverse agonist at the 5HT2A receptor and has a 40-fold weaker antagonism/inverse agonism at the 5HT2C receptor.

Pimavanserin metabolism primarily occurs in the liver; it is a CYP450 enzyme-substrate, primarily CYP3A4/5, but also CYP2D6 and CYP2J2. It has an active metabolite. The drug has a half-life of 57 hours for the parent drug and 200 hours for the active metabolite. It is excreted in the urine and feces.